130 related articles for article (PubMed ID: 18670853)
1. Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET.
Ye Z; Zhu J; Tian M; Zhang H; Zhan H; Zhao C; Yang D; Li W; Lin N
Ann Nucl Med; 2008 Jul; 22(6):475-80. PubMed ID: 18670853
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
Hamada K; Tomita Y; Inoue A; Fujimoto T; Hashimoto N; Myoui A; Yoshikawa H; Hatazawa J
Ann Nucl Med; 2009 Jan; 23(1):89-95. PubMed ID: 19205843
[TBL] [Abstract][Full Text] [Related]
3. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.
Palmerini E; Colangeli M; Nanni C; Fanti S; Marchesi E; Paioli A; Picci P; Cambioli S; Donati D; Cevolani L; De Paolis M; Gambarotti M; Ferrari S
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):215-223. PubMed ID: 27645694
[TBL] [Abstract][Full Text] [Related]
4. Tumor-to-background ratio to predict response to chemotherapy of osteosarcoma better than standard uptake values.
He JP; Hao Y; Li M; Wang J; Guo FJ
Orthop Surg; 2014 May; 6(2):145-53. PubMed ID: 24890297
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.
Schulte M; Brecht-Krauss D; Werner M; Hartwig E; Sarkar MR; Keppler P; Kotzerke J; Guhlmann A; Delling G; Reske SN
J Nucl Med; 1999 Oct; 40(10):1637-43. PubMed ID: 10520703
[TBL] [Abstract][Full Text] [Related]
6. Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis.
Bajpai J; Kumar R; Sreenivas V; Sharma MC; Khan SA; Rastogi S; Malhotra A; Gamnagatti S; Kumar R; Safaya R; Bakhshi S
J Pediatr Hematol Oncol; 2011 Oct; 33(7):e271-8. PubMed ID: 22193290
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.
Hawkins DS; Rajendran JG; Conrad EU; Bruckner JD; Eary JF
Cancer; 2002 Jun; 94(12):3277-84. PubMed ID: 12115361
[TBL] [Abstract][Full Text] [Related]
8. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
[TBL] [Abstract][Full Text] [Related]
9. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors.
Hawkins DS; Schuetze SM; Butrynski JE; Rajendran JG; Vernon CB; Conrad EU; Eary JF
J Clin Oncol; 2005 Dec; 23(34):8828-34. PubMed ID: 16314643
[TBL] [Abstract][Full Text] [Related]
10. [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.
Hawkins DS; Conrad EU; Butrynski JE; Schuetze SM; Eary JF
Cancer; 2009 Aug; 115(15):3519-25. PubMed ID: 19517457
[TBL] [Abstract][Full Text] [Related]
11. Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT.
Byun BH; Kim SH; Lim SM; Lim I; Kong CB; Song WS; Cho WH; Jeon DG; Lee SY; Koh JS; Chung SK
Eur Radiol; 2015 Jul; 25(7):2015-24. PubMed ID: 25680716
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis.
Franzius C; Sciuk J; Brinkschmidt C; Jürgens H; Schober O
Clin Nucl Med; 2000 Nov; 25(11):874-81. PubMed ID: 11079583
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis.
Hongtao L; Hui Z; Bingshun W; Xiaojin W; Zhiyu W; Shuier Z; Aina H; Yuanjue S; Daliu M; Zan S; Yang Y
Surg Oncol; 2012 Dec; 21(4):e165-70. PubMed ID: 22884956
[TBL] [Abstract][Full Text] [Related]
15. Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor.
Qin Z; Tang Y; Wang H; Cai W; Fu H; Li J; Ma C
J Pediatr Hematol Oncol; 2015 Jul; 37(5):396-401. PubMed ID: 25749587
[TBL] [Abstract][Full Text] [Related]
16. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.
Cheon GJ; Kim MS; Lee JA; Lee SY; Cho WH; Song WS; Koh JS; Yoo JY; Oh DH; Shin DS; Jeon DG
J Nucl Med; 2009 Sep; 50(9):1435-40. PubMed ID: 19690035
[TBL] [Abstract][Full Text] [Related]
17. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.
Im HJ; Kim TS; Park SY; Min HS; Kim JH; Kang HG; Park SE; Kwon MM; Yoon JH; Park HJ; Kim SK; Park BK
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):39-49. PubMed ID: 21953008
[TBL] [Abstract][Full Text] [Related]
18. Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma.
Raciborska A; Bilska K; Drabko K; Michalak E; Chaber R; Pogorzała M; Połczyńska K; Sobol G; Wieczorek M; Muszyńska-Rosłan K; Rychlowska-Pruszyńska M; Rodriguez-Galindo C; Dziuk M
Clin Transl Oncol; 2016 Feb; 18(2):189-95. PubMed ID: 26250765
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography (18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma: A meta-analysis.
Li YJ; Dai YL; Cheng YS; Zhang WB; Tu CQ
Eur J Surg Oncol; 2016 Aug; 42(8):1103-14. PubMed ID: 27189833
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma.
Costelloe CM; Macapinlac HA; Madewell JE; Fitzgerald NE; Mawlawi OR; Rohren EM; Raymond AK; Lewis VO; Anderson PM; Bassett RL; Harrell RK; Marom EM
J Nucl Med; 2009 Mar; 50(3):340-7. PubMed ID: 19258257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]